New concepts on the role of human papillomavirus in cell cycle regulation.

Human papillomaviruses (HPVs) are strictly host-specific and also show a distinct tropism to squamous epithelial cells. Upon HPV infection, only a portion of the virus reaching the nucleus seems to undergo replication, suggesting that HPV replication remains confined to a small number of cells. HPVs critically depend on the cellular machinery for the replication of their genome. Viral replication is restricted to differentiated keratinocytes that are normally growth arrested. Hence, HPVs have developed strategies to subvert cellular growth regulatory pathways and are able to uncouple cellular proliferation and differentiation. Endogenous growth factors and cellular oncogenes modify HPV E (early) and L (late) gene expression and influence on the pathogenesis of HPV infections. HPV oncoproteins (E5, E6, E7) are important proteins not only in cell transformation but also in the regulation of the mitotic cycle of the cell, thus allowing the continuous proliferation of the host cells. Cyclins are important regulators of cell cycle transitions through their ability to bind cyclin-dependent kinases (cdks). Cdks have no kinase activity unless they are associated with a cyclin. Several classes of cyclins exist which are thought to coordinate the timing of different events necessary for cell cycle progression. Each cdk catalytic subunit can associate with different cyclins, and the associated cyclin determines which proteins are phosphorylated by the cdk-cyclin complex. The effects of HPVs on the cell cycle are mediated through the inhibition of antioncogens (mostly p53 and retinoblastoma) and through interference with the cyclins and cdks, resulting in target cell proliferation, their delayed differentiation, and as a side-effect, in malignant transformation.

[1]  S. Syrjänen,et al.  Papillomavirus Infections in Human Pathology , 2000 .

[2]  A. Kristjuhan,et al.  p53 Protein Is a Suppressor of Papillomavirus DNA Amplificational Replication , 1998, Journal of Virology.

[3]  A. Ciechanover,et al.  Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Scheffner,et al.  The ubiquitin-protein ligase E6-associated protein (E6-AP) serves as its own substrate. , 1998, European journal of biochemistry.

[5]  H. Drexler Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia–lymphoma cells , 1998, Leukemia.

[6]  E. Auvinen,et al.  The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. , 1998, Experimental cell research.

[7]  M Fujita,et al.  Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  E. Flores,et al.  Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle , 1997, Journal of virology.

[9]  S. O. Smith,et al.  Identification of amino acids in the transmembrane and juxtamembrane domains of the platelet-derived growth factor receptor required for productive interaction with the bovine papillomavirus E5 protein , 1997, Journal of virology.

[10]  E. Auvinen,et al.  Enhancement of EGF- and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein , 1997, Oncogene.

[11]  D. Fishman,et al.  Linking protein kinase C to cell-cycle control. , 1997, European journal of biochemistry.

[12]  D. Pim,et al.  Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth , 1997, Oncogene.

[13]  L. Laimins,et al.  Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity , 1997, Journal of virology.

[14]  H. Shirasawa,et al.  Transactivation of Prothymosin α and c-mycPromoters by Human Papillomavirus Type 16 E6 Protein , 1997 .

[15]  K. Vousden,et al.  Perturbation of the p53 response by human papillomavirus type 16 E7 , 1997, Journal of virology.

[16]  C. Gao,et al.  Cyclins, cyclin‐dependent kinases and differentiation , 1997, BioEssays : news and reviews in molecular, cellular and developmental biology.

[17]  S. Moreno,et al.  Regulation of CDK/cyclin complexes during the cell cycle. , 1997, The international journal of biochemistry & cell biology.

[18]  K. Münger,et al.  Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein , 1997, Journal of virology.

[19]  J. Brock,et al.  HPV-Typen vom “high risk type” in oralen und laryngealen Papillomen und Leukoplakien* , 1997 .

[20]  E. Villiers Papillomavirus and HPV typing. , 1997 .

[21]  G. Orth,et al.  Commentary to part one , 1997 .

[22]  N. Ramoz,et al.  Human papillomaviruses: general features. , 1997, Clinics in dermatology.

[23]  M. Yaniv,et al.  Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis , 1997, The EMBO journal.

[24]  L. Banks,et al.  Repression of p53 transcriptional activity by the HPV E7 proteins. , 1997, Virology.

[25]  C. Calef,et al.  Heterogeneity of papillomaviruses. , 1996, Seminars in cancer biology.

[26]  T. Wright,et al.  Anogenital papillomavirus infection and neoplasia in immunodeficient women. , 1996, Obstetrics and gynecology clinics of North America.

[27]  Y. Tsao,et al.  Human papillomavirus type 11 and 16 E5 represses p21(WafI/SdiI/CipI) gene expression in fibroblasts and keratinocytes , 1996, Journal of virology.

[28]  Harald zur Hausen,et al.  Papillomavirus infections — a major cause of human cancers , 1996 .

[29]  M. Kubbutat,et al.  Role of E6 and E7 oncoproteins in HPV-induced anogenital malignancies , 1996 .

[30]  Lawrence Da Transforming growth factor-beta: a general review. , 1996, European cytokine network.

[31]  H. Wang,et al.  Kinetics of HPV11 DNA replication after infection of keratinocytes with virions. , 1996, Virus research.

[32]  K. Wiman,et al.  Abrogation of p53-induced G1 arrest by the HPV 16 E7 protein does not inhibit p53-induced apoptosis. , 1996, Oncogene.

[33]  D. Pim,et al.  HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. , 1996, Oncogene.

[34]  Y. Tsao,et al.  Mutational analysis of human papillomavirus type 11 E5a oncoprotein , 1996, Journal of virology.

[35]  B. Shan,et al.  The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[36]  M. Birrer,et al.  The human papillomavirus type 16 E7 gene product interacts with and trans‐activates the AP1 family of transcription factors. , 1996, The EMBO journal.

[37]  E. Androphy,et al.  Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells , 1996, Journal of virology.

[38]  M. Oren,et al.  Specific loss of apoptotic but not cell‐cycle arrest function in a human tumor derived p53 mutant. , 1996, The EMBO journal.

[39]  G. Matlashewski,et al.  Effect of human papillomavirus type 16 oncogenes on MAP kinase activity , 1995, Journal of virology.

[40]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[41]  D. DiMaio,et al.  Mutational analysis of the interaction between the bovine papillomavirus E5 transforming protein and the endogenous beta receptor for platelet-derived growth factor in mouse C127 cells , 1995, Journal of virology.

[42]  R. Schlegel,et al.  The human papilloma virus 16E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[43]  E. Androphy,et al.  Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. , 1995, Science.

[44]  X. Graña,et al.  Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). , 1995, Oncogene.

[45]  R. Schlegel,et al.  E5 oncoprotein retained in the endoplasmic reticulum/cis Golgi still induces PDGF receptor autophosphorylation but does not transform cells. , 1995, The EMBO journal.

[46]  L. Crawford,et al.  Cell cycle-dependent disruption of E2F-p107 complexes by human papillomavirus type 16 E7. , 1995, The Journal of general virology.

[47]  A. Burny,et al.  Wild-type p53 down-regulates transcription from oncogenic human papillomavirus promoters through the epithelial specific enhancer. , 1995, Oncogene.

[48]  D. DiMaio,et al.  Ligand-independent activation of the platelet-derived growth factor beta receptor: requirements for bovine papillomavirus E5-induced mitogenic signaling , 1995, Molecular and cellular biology.

[49]  D. McCance,et al.  The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes , 1995, Journal of virology.

[50]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[51]  E. Androphy,et al.  The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain. , 1995, Oncogene.

[52]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[53]  D. Galloway,et al.  The E6 protein of human papillomavirus type 16 functions as a transcriptional repressor in a mechanism independent of the tumor suppressor protein, p53. , 1994, Virology.

[54]  D. Beach,et al.  Cyclin G is a transcriptional target of the p53 tumor suppressor protein. , 1994, The EMBO journal.

[55]  A. Ciechanover The ubiquitin-mediated proteolytic pathway: mechanisms of action and cellular physiology. , 1994, Biological chemistry Hoppe-Seyler.

[56]  T. Crook,et al.  Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. , 1994, Oncogene.

[57]  F. Carlotti,et al.  Functional studies of E7 proteins from different HPV types. , 1994, Oncogene.

[58]  L. Banks,et al.  The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. , 1994, Virology.

[59]  J. Pines,et al.  The cell cycle kinases. , 1994, Seminars in cancer biology.

[60]  A. Lamond,et al.  The endoplasmic reticulum calcium-binding protein of 55 kDa is a novel EF-hand protein retained in the endoplasmic reticulum by a carboxyl-terminal His-Asp-Glu-Leu motif. , 1994, The Journal of biological chemistry.

[61]  F. Hoppe-Seyler,et al.  Cellular control of human papillomavirus oncogene transcription , 1994, Molecular carcinogenesis.

[62]  Miranda Thomas,et al.  Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. , 1994, Oncogene.

[63]  M. Lechner,et al.  Inhibition of p53 DNA binding by human papillomavirus E6 proteins , 1994, Journal of virology.

[64]  D. DiMaio,et al.  Specific interaction between the bovine papillomavirus E5 transforming protein and the beta receptor for platelet-derived growth factor in stably transformed and acutely transfected cells , 1994, Journal of virology.

[65]  A. N. Meyer,et al.  Cellular transformation by a transmembrane peptide: structural requirements for the bovine papillomavirus E5 oncoprotein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[66]  T. Andrésson,et al.  The E5 protein of HPV-6, but not HPV-16, associates efficiently with cellular growth factor receptors. , 1994, Virology.

[67]  R. Elston,et al.  Interaction of the E6 protein of human papillomavirus with cellular proteins. , 1994, Oncogene.

[68]  Y. Moon,et al.  Expression and localization of human papillomavirus type 16 E6 and E7 open reading frame proteins in human epidermal keratinocyte. , 1994, Yonsei medical journal.

[69]  T. Crook,et al.  Interaction of HPV E6 with p53 and associated proteins. , 1994, Biochemical Society transactions.

[70]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[71]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[72]  M. Scheffner,et al.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.

[73]  K. Helin,et al.  Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. , 1993, Genes & development.

[74]  D. Lowy,et al.  Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain , 1993, Journal of virology.

[75]  D. McCance,et al.  The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes , 1993, Journal of virology.

[76]  K. Vousden Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes , 1993 .

[77]  Charles J. Sherr,et al.  Mammalian G1 cyclins , 1993, Cell.

[78]  T. Crook,et al.  Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation , 1993, Journal of virology.

[79]  D. W. Maher,et al.  Alanine mutagenesis of conserved residues in the platelet-derived growth factor family: identification of residues necessary for dimerization and transformation. , 1993, Oncogene.

[80]  V. Garsky,et al.  Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein , 1993, Molecular and cellular biology.

[81]  M. Oren,et al.  mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.

[82]  B. Lin,et al.  Tamoxifen stimulates human papillomavirus type 16 gene expression and cell proliferation in a cervical cancer cell line. , 1992, Cancer research.

[83]  R. Schlegel,et al.  The BPV‐1 E5 protein, the 16 kDa membrane pore‐forming protein and the PDGF receptor exist in a complex that is dependent on hydrophobic transmembrane interactions. , 1992, The EMBO journal.

[84]  K. Münger,et al.  Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins , 1992, Journal of virology.

[85]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[86]  J. Minna,et al.  Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins , 1992, Journal of virology.

[87]  D. DiMaio,et al.  Stable association between the bovine papillomavirus E5 transforming protein and activated platelet-derived growth factor receptor in transformed mouse cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[88]  S. Weintraub,et al.  Retinoblastoma protein switches the E2F site from positive to negative element , 1992, Nature.

[89]  E. Androphy,et al.  Mechanism of action of the papillomavirus E2 repressor: repression in the absence of DNA binding , 1992, Journal of virology.

[90]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[91]  J. Nevins,et al.  Analysis of trans activation by human papillomavirus type 16 E7 and adenovirus 12S E1A suggests a common mechanism , 1991, Journal of virology.

[92]  M. Scheffner,et al.  A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. , 1991, The EMBO journal.

[93]  D. DiMaio,et al.  Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16 , 1991, Journal of virology.

[94]  K. Vousden,et al.  Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation , 1991, Cell.

[95]  P. Howley,et al.  The papillomavirus E2 regulatory proteins. , 1991, The Journal of biological chemistry.

[96]  D. DiMaio,et al.  Biological properties of the deer papillomavirus E5 gene in mouse C127 cells: growth transformation, induction of DNA synthesis, and activation of the platelet-derived growth factor receptor , 1991, Journal of virology.

[97]  D. Lowy,et al.  The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture , 1991, Journal of virology.

[98]  G. Demers,et al.  The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells , 1991, Journal of virology.

[99]  H. Bernard Controls in the papillomavirus life cycle. , 1990, FEMS microbiology immunology.

[100]  A. Levine,et al.  Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.

[101]  R. Eisenman,et al.  The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. , 1989, The New biologist.

[102]  K. Münger,et al.  The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. , 1989, Science.

[103]  M. Yaniv,et al.  Study of the E2 gene product of the cottontail rabbit papillomavirus reveals a common mechanism of transactivation among papillomaviruses , 1988, Journal of virology.

[104]  D. Galloway,et al.  Identification of the E5 open reading frame of human papillomavirus type 16 , 1988, Journal of virology.

[105]  D. McCance,et al.  DNA sequence of the HPV-16 E5 ORF and the structural conservation of its encoded protein. , 1988, Virology.

[106]  O'Connor Pm Mammalian G1 and G2 phase checkpoints. , 1997 .

[107]  L. Villa Human papillomaviruses and cervical cancer. , 1997, Advances in cancer research.

[108]  X. Graña,et al.  pRB, p107 and p130 as transcriptional regulators: role in cell growth and differentiation. , 1997, Progress in cell cycle research.

[109]  L. Laimins,et al.  Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. , 1996, Virology.

[110]  H. Hausen Viruses In Human Tumors–Reminiscences And Perspectives , 1996 .

[111]  A. Giordano,et al.  Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. , 1995, Critical reviews in eukaryotic gene expression.

[112]  A. Amerik,et al.  The DOA pathway: studies on the functions and mechanisms of ubiquitin-dependent protein degradation in the yeast Saccharomyces cerevisiae. , 1995, Cold Spring Harbor symposia on quantitative biology.

[113]  J. Sobczak-Thépot,et al.  Cyclin A: function and expression during cell proliferation. , 1995, Progress in cell cycle research.

[114]  G. Demers,et al.  Cell cycle checkpoint control is bypassed by human papillomavirus oncogenes. , 1994, Cold Spring Harbor symposia on quantitative biology.

[115]  P. Fuchs,et al.  Anatomy, taxonomy and evolution of papillomaviruses. , 1994, Intervirology.

[116]  L. Turek The structure, function, and regulation of papillomaviral genes in infection and cervical cancer. , 1994, Advances in virus research.

[117]  E. Villiers Human Pathogenic Papillomavirus Types: An Update , 1994 .

[118]  H. Hausen,et al.  Human Pathogenic Papillomaviruses , 1994, Current Topics in Microbiology and Immunology.

[119]  P. Fuchs,et al.  Transcription of papillomavirus genomes. , 1994, Intervirology.

[120]  M. Stanley,et al.  Human papillomaviruses and cervical cancer : biology and immunology , 1994 .

[121]  D. Mccance Human papillomaviruses. , 1994, Infectious disease clinics of North America.

[122]  T. Crook,et al.  Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling. , 1993, Oncogene.

[123]  T. Hunt,et al.  HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. , 1993, Oncogene.

[124]  L. Banks,et al.  The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. , 1992, Oncogene.

[125]  D. Pim,et al.  Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. , 1992, Oncogene.

[126]  J. Gauthier,et al.  The papillomavirus E2 protein: a factor with many talents. , 1991, Trends in biochemical sciences.

[127]  V. Band,et al.  Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. , 1990, Proceedings of the National Academy of Sciences of the United States of America.